TMCnet12m
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Skye launched its Phase 2 trial of nimacimab in obesity in August 2024. This trial, which is the first to also assess a GLP-1/CB1 inhibitor combination, is expected to report interim weight loss data ...
Analysts say market forces will lower cost of obesity drugs
Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.
Questions over Novo Nordisk $1bn weight loss drug after Phase IIa trial
Novo Nordisk acquired monlunabant in a $1bn deal last year, but the Phase IIa trial raises questions over the efficacy and ...
Fed Uncertainty Is History. Now Markets Need to Brace for Election Volatility.
A gradual descent seems the most likely scenario.To be sure, the stock market is still digesting what the Fed has done.